Drug intelligence / Profile preview

JUV001

Development stage: Preclinical
Lead developer: FoxBio
Modality: Small Molecules
Administration: Subcutaneous

Overview

JUV001 is a small molecule senolytic drug under development by FoxBio, a joint venture formed by Juvenescence and Antoxerene. It is being developed for the treatment of osteoarthritis. The drug's mechanism of action involves targeting the FOXO4-p53 interaction to selectively destroy senescent cells, which are implicated in various age-related diseases.

Targets

FOXO3 (Forkhead box protein O3)

Beyond the preview

Go deeper on JUV001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JUV001.

Explore the full profile